,i #aagth ,,congress #b;d ,session ,h4 ,r4 #gjdg ,,in ,,the ,,house ,,of ,,representatives ,march #i1 #bjbb,mr4 ,schrader introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to amend title ,,iii of the ,public ,health ,service ,act with respect to the determination by the ,secretary regarding certain biosimilar application elements1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,lowering ,costs by ,improving ,biosimilar ,uptake ,act4 #b4 ,determination by ,secretary regarding certain biosimilar application elements ,section #cea7k77#b77;,a77ii7 of the ,public ,health ,service ,act 7#bfb7k77#b77;,a77ii77 is amended to read as follows3 7ii7 ,determination by secretary regarding certain application elements 7,i7 ,in general ,the ,secretary may determine1 in the ,secretary's discretion1 that an element described in clause 7i77,i71 or in clause 7i77,,iv7 with respect to the strength of a biological product1 is unnecessary in an application submitted under this subsection4 7,,ii7 ,use of determination ,if the ,secretary makes a determination under this clause that information demonstrating that the strength of the biological product is the same as that of the reference product as described in clause 7i77,,iv7 is unnecessary1 the term reference product shall1 for purposes of this section with respect to such biological product1 include all applicable strengths of the reference product4 4